BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies.

Products, services, technology

Key products for outlicensing are :

- Sublingual exenatide

- Sublingual liraglutide

- Sublingual insulin+

- low dose sublingual IL2 for auto-immune disorders

Cooperation possibilities

BioLingus is open to partner its platform technology for development of products with other companies (eg peptides)

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2014
  • Number of employees in Switzerland
    1-9